Arcutis Biotherapeutics, Inc. (ARQT) - Q1 2026 10-Q Summary
Business Context and Reporting Period
This report covers the quarterly period ended March 31, 2026. Arcutis Biotherapeutics is a commercial-stage biopharmaceutical company focused on dermatological diseases. Its primary commercial product is ZORYVE (roflumilast), available in cream and foam formulations for plaque psoriasis, seborrheic dermatitis, and atopic dermatitis. The company is also advancing ARQ-234, a systemic treatment for atopic dermatitis, which entered Phase 1a/1b clinical trials in March 2026.
Key Financial Metrics
| Metric | Q1 2026 | Q1 2025 |
|---|---|---|
| Total Revenues | $105.4 million | $65.8 million |
| Net Loss | $(11.3) million | $(25.1) million |
| Net Loss Per Share | $(0.09) | $(0.20) |
| Operating Cash Flow | $2.2 million | $(30.4) million |
| Cash & Marketable Securities | $224.3 million | $221.3 million (Dec 31, 2025) |
| Total Debt (Principal) | $100.0 million | $100.0 million |
| Accumulated Deficit | $(1,149.4) million | $(1,138.1) million (Dec 31, 2025) |
Material Changes vs. Prior Period
- Revenue Growth: Total revenue increased 65% year-over-year to $105.4 million, driven by strong demand for ZORYVE foam (up 64%) and ZORYVE cream 0.15% (up 113%).
- Improved Profitability: Net loss narrowed significantly to $11.3 million from $25.1 million in Q1 2025. Operating loss decreased to $9.1 million from $24.5 million.
- Cash Flow Turnaround: The company generated positive operating cash flow of $2.2 million, compared to a use of $30.4 million in the prior year, largely due to improved collections and working capital management.
- R&D Spike: Research and development expenses increased 75% to $30.6 million. This was primarily due to a $10.0 million milestone payment triggered by the first patient dosing in the ARQ-234 Phase 1a/1b trial.
- Debt Structure: The company maintained $100.0 million in outstanding term loans. The tranche C-1 availability expired on March 31, 2026, and tranche C-2 expires June 30, 2026.
Guidance, Outlook, and Risks
- Liquidity: Management believes existing capital resources ($224.3 million in cash/securities) are sufficient to fund operations for at least 12 months. No immediate financing is anticipated, though future needs depend on commercialization and development costs.
- Commercial Updates: The promotion agreement with Kowa Pharmaceuticals was terminated effective January 23, 2026. Arcutis will now manage primary care and pediatric promotion internally.
- Regulatory Milestones: An sNDA for ZORYVE cream 0.3% for children aged 2-5 was accepted by the FDA in November 2025 (PDUFA date June 29, 2026). An sNDA for ZORYVE cream 0.05% for infants (3 months to 2 years) was submitted in April 2026.
- Legal Proceedings: Patent litigation against Padagis regarding a generic ZORYVE 0.3% cream is currently stayed. The automatic 30-month stay of FDA approval for the generic is set to expire August 14, 2026, but is extended for the duration of the stay.
- Risks: Risks include the uncertainty of clinical trial outcomes for ARQ-234, potential failure to meet debt covenants (minimum net product revenue), and the impact of generic competition upon patent expiration.
Investor Verification Checklist
- Debt Covenants: Verify compliance with the minimum net product revenue covenant (75% of projected annual plan) tested on a trailing six-month basis.
- ARQ-234 Progress: Monitor the timeline and results of the Phase 1a/1b trial for ARQ-234, which triggered a significant $10M expense in Q1.
- Generic Competition: Track the status of the Padagis litigation and the August 2026 expiration of the 30-month stay on the generic ZORYVE ANDA.
- Debt Maturity: Note the $100M principal debt maturity date of August 1, 2029, and the upcoming expiration of tranche C-2 availability in June 2026.
- Regulatory Decisions: Watch for the FDA decision on the ZORYVE cream 0.3% pediatric expansion (PDUFA June 29, 2026).